(SWOG 1404) A Phase III Randomized Trial Comparing Physican/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
Description: 
To compare overall survival (OS) of patients with resected Stage III and IV melanoma treated with physician/patient choice of either high dose interferon alfa-2b or ipilimumab versus MK-3475 (pembrolizumab).
Study Number: 

NCG 283816

Phase: 
3
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02506153

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.